ITOS News and Press, iTeos Therapeutics Inc. From 04/17/21

The first week of AACR 2021 (American Association of Cancer Research Annual Meeting) has concluded with Affimed (AFMD) emerging as a clear winner while iTeos Therapeutics (ITOS) disappointed with an early-stage study for its lead asset.The presentations from Eli Lilly (LLY), Oncternal Therape...

Initial data from the Phase 1 dose escalation part of the Phase 1/2a trial in adult patients with advanced solid tumors indicated EOS-448 was generally well tolerated with no dose-limiting toxicities observed EOS-448 showed preliminary signs of clinical activity as a monothe...

An abstract posted ahead of AACR annual meeting 2021 demonstrates the initial data from an early-stage study for solid tumors evaluating the safety and tolerability of EOS-448, one of the lead assets of iTeos Therapeutics (ITOS).EOS-448 is an anti-TIGIT human immunoglobulin G1 that has t...

Wedbush analyst David Nierengarten is maintaining his overweight rating on shares of iTeos Therapeutics (ITOS) and increasing his price target to $52 from $46.Nierengarten is bullish on upcoming phase 1/2 results on EOS-448 for immune-resistant advanced cancers that will be presented next mon...

iTeos Therapeutics (ITOS): Q4 GAAP EPS of -$0.43 misses by $0.01.The Company’s cash and cash equivalent position was $336.3 million as of December 31, 2020, as compared to $19.9 million as of December 31, 2019. Cash balance provides runway into second half of 2023.Press Release ...

– Initial data from Phase 1/2a trial of EOS-448 to be presented at American Association for Cancer Research Annual Meeting. Company to hold conference call at 8:00 am on April 12 th to discuss results – – Updated, single-agent data of inupadenant (...

The following slide deck was published by iTeos Therapeutics, Inc. in conjunction with this event. For further details see: iTeos Therapeutics (ITOS) Investor Presentation - Slideshow

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 23, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, tod...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 17, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, tod...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead The Q4 earnings season cranks up with Procter & Gamble (NYSE:PG), Netflix (NASDAQ:NFLX) and Intel (NASDAQ:INTC) some...